Bovela (modified live bovine viral diarrhoea...) – Summary of product characteristics - QI02AD02
Updated on site: 08-Feb-2018
|Substance:||modified live bovine viral diarrhoea virus type 1, non-cytopathic parent strain KE-9 and modified live bovine viral diarrhoea virus type 2, non-cytopathic parent strain NY-93|
|Manufacturer:||Boehringer Ingelheim Vetmedica GmbH|
- 1. NAME OF THE VETERINARY MEDICINAL PRODUCT
- 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
- 3. PHARMACEUTICAL FORM
- 4. CLINICAL PARTICULARS
- 4.1 Target species
- 4.2 Indications for use, specifying the target species
- 4.3 Contraindications
- 4.4 Special warnings for each target species
- 4.5 Special precautions for use
- 4.6 Adverse reactions (frequency and seriousness)
- 4.7 Use during pregnancy, lactation or lay
- 4.8 Interaction with other medicinal products and other forms of interaction
- 4.9 Amounts to be administered and administration route
- 4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary
- 4.11 Withdrawal period
- 5. IMMUNOLOGICAL PROPERTIES
- 6. PHARMACEUTICAL PARTICULARS
- 7. MARKETING AUTHORISATION HOLDER
- 8. MARKETING AUTHORISATION NUMBER(S)
- 9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
- 10. DATE OF REVISION OF THE TEXT
1.NAME OF THE VETERINARY MEDICINAL PRODUCT
Bovela lyophilisate and solvent for suspension for injection for cattle.
2.QUALITATIVE AND QUANTITATIVE COMPOSITION
Each dose (2 ml) contains:
*Bovine viral diarrhoea virus
**Tissue culture infectious dose 50%
For the full list of excipients, see section 6.1.
Lyophilisate and solvent for suspension for injection
Solvent: Clear, colourless solution.
4.2Indications for use, specifying the target species
For active immunisation of cattle from 3 months of age to reduce hyperthermia and to minimise the reduction of leukocyte count caused by bovine viral diarrhoea virus
For active immunisation of cattle against
Onset of immunity:
3 weeks after immunisation.
Duration of immunity:
Do not use in cases of hypersensitivity to the active substances or to any of the excipients.
4.4Special warnings for each target species
Vaccinate healthy animals only.
To ensure the protection of animals introduced to the herd where BVDV is circulating, vaccination has to be completed 3 weeks before introduction.
The cornerstone of bovine viral diarrhoea
The field studies to investigate the efficacy of the vaccine were done in herds where persistently infected animals had been removed.
4.5Special precautions for use
Special precautions for use in animals:
Longlasting viremia has been observed after vaccination, in particular in pregnant seronegative heifers (10 days in a study). This may result in transplacental transmission on the vaccine virus, but no adverse effects on foetus or pregnancy was observed in studies.
Shedding of the vaccine virus by body fluids cannot be excluded.
The vaccine strains are able to infect sheep and swine when administered intranasally, but no adverse reactions or spreading to
The vaccine has not been tested in breeding bulls and should therefore not be used in breeding bulls.
Special precautions to be taken by the person administering the veterinary medicinal product to animals:
In case of accidental
4.6Adverse reactions (frequency and seriousness)
Mild swellings or nodules up to 3 cm diameter were observed at the injection site and disappeared within 4 days post vaccination.
An increase in body temperature within the physiological range is common within 4 hours of vaccination and spontaneously resolves within 24 hours.
The frequency of adverse reactions is defined using the following convention:
-very common (more than 1 in 10 animals treated displaying adverse reactions)
-common (more than 1 but less than 10 animals in 100 animals treated)
-uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
-rare (more than 1 but less than 10 animals in 10,000 animals treated)
-very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
4.7Use during pregnancy, lactation or lay
It is recommended to vaccinate before pregnancy to ensure protection against persistent infection of the foetus. While persistent infection of the foetus caused by the vaccine was not observed, transmission of vaccine virus to the foetus may occur. Therefore, use during pregnancy should only be on a
Can be used during lactation.
Studies have shown that vaccine virus may be excreted in milk up to 23 days after vaccination at low amounts (~ 10 TCID50/ml), although when such milk was fed to calves, no seroconversion occurred in those calves.
4.8Interaction with other medicinal products and other forms of interaction
No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.
4.9Amounts to be administered and administration route
Preparation of vaccine for use (reconstitution):
Reconstitute the lyophilisate by adding the full content of the solvent at room temperature. Ensure that the lyophilisate is completely reconstituted before use.
The reconstituted vaccine is transparent and colourless. Avoid multiple broaching.
After reconstitution, administer one dose (2 ml) of the vaccine by intramuscular (IM) injection.
It is recommended to vaccinate cattle at least 3 weeks before insemination/mating to provide foetal protection from the first day of conception. Animals which are vaccinated later than 3 weeks before gestation or during the early gestation may not be protected against foetal infection. This should be considered in case of herd vaccination.
- Novem - Boehringer Ingelheim Vetmedica GmbH
- Semintra - Boehringer Ingelheim Vetmedica GmbH
- Metacam - Boehringer Ingelheim Vetmedica GmbH
- Pexion - Boehringer Ingelheim Vetmedica GmbH
- Prozinc - Boehringer Ingelheim Vetmedica GmbH
Prescription drugs listed. Manufacturer: "Boehringer Ingelheim Vetmedica GmbH"
12 months after primary vaccination most studied animals still had antibody titres at plateau while some animals had lower titres.
4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary
Mild swellings or nodules up to 3 cm diameter were observed at the injection site after administration of a
Furthermore, an increase of the rectal body temperature was common within 4 hours following administration and spontaneously resolves within 24 hours (see section 4.6).
4.11 Withdrawal period
Pharmacotherapeutic group: immunologicals for bovidae, live viral vaccines. ATCvet code: QI02AD02.
The vaccine is designed to stimulate the development of an active immune response against
6.1List of excipients
Potassium dihydrogen phosphate
Water for injections
Potassium dihydrogen phosphate
Disodium hydrogen phosphate
Water for injections
Do not mix with any other veterinary medicinal product, except solvent supplied for use with the veterinary medicinal product.
Shelf life of the veterinary medicinal product as packaged for sale: 2 years. Solvent:
Shelf life of the solvent:3 years. Shelf life after reconstitution according to directions: 8 hours.
6.4Special precautions for storage
Store and transport refrigerated (2 °C – 8 °C).
Do not freeze.
Keep the lyophilisate and the solvent vials in the outer carton.
6.5Nature and composition of immediate packaging
1, 4, 6 or 10 type I amber glass vials containing 5 doses (10 ml), 10 doses (20 ml), 25 doses (50 ml) and 50 doses (100 ml) of lyophilisate, closed with siliconised bromobutyl rubber stopper with lacquered aluminium seal.
1, 4, 6 or 10 high density polyethylene (HDPE) bottles containing 10 ml, 20 ml, 50 ml and 100 ml of solvent, closed with a siliconised chlorobutyl rubber stopper with lacquered aluminium seal.
Corresponding vials of vaccine and bottles of solvent are packed in cardboard boxes together.
Not all pack sizes may be marketed.
6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
7.MARKETING AUTHORISATION HOLDER
Boehringer Ingelheim Vetmedica GmbH
8.MARKETING AUTHORISATION NUMBER(S)
9.DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
Date of first authorisation: 22.12.2014
10.DATE OF REVISION OF THE TEXT
Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu/.
PROHIBITION OF SALE, SUPPLY AND/OR USE
Any person intending to manufacture, import, possess, sell, supply and use this veterinary medicinal product must first consult the relevant Member State’s competent authority on the current vaccination policies, as these activities may be prohibited in a Member State on the whole or part of its territory pursuant to national legislation.